SAN DIEGO—When it comes to laryngopharyngeal reflux (LPR), the standard treatment is clear: proton pump inhibitors (PPIs). But, as experts explained here at the American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting, an array of options is out there, many of them non-pharmaceutical.
Explore this issue:December 2016
LPR occurs in an estimated 30% to 40% of the adult population in the United States, with a higher incidence among people who are obese, are older, smoke, suffer from high stress, and consume certain diets, said Marilene Wang, MD, professor of head and neck surgery at the University of California, Los Angeles (UCLA) School of Medicine.
Debate Over Treatment
Michele Morrison, DO, FACS, a laryngologist and chair of otolaryngology-head and neck surgery at Naval Medical Center in Portsmouth, Va., said that while LPR has been accepted as a separate entity from gastroesophageal reflux, there is some lingering debate over the condition’s diagnosis and management. LPR can lead to a variety of symptoms, including chronic mucosal injury, laryngitis, and granulomas, as well as pulmonary issues such as pneumonia, and can be a trigger for head and neck cancers, including esophageal cancer and laryngeal and pharyngeal squamous cell carcinomas.| | | Next → | Single Page